Symbiomix Therapeutics, LLC — Form D/A
Symbiomix Therapeutics, LLC of NEWARK, NJ, a company, filed a Form D amendment with the SEC on 2014-07-09. The offering totals $32.5M, of which $19.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2014-07-09
- Form: D/A
- Accession: 0001612502-14-000002
- Industry: Pharmaceuticals
- Exemptions: 06c
- Total offering: $32.5M
- Amount sold: $19.5M
- Remaining: $13.0M
- Investors: 5
- Date of first sale: 2013-05-03
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-220646
Issuer
- Name: Symbiomix Therapeutics, LLC
- CIK: 0001612502
- Entity type: Limited Liability Company
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 105 LOCK STREET SUITE 409, NEWARK, NJ, 07103
- Phone: 609-722-7250
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Robert Jacks | Director | Portland, OR |
| Rishi Gupta | Director | New York, NY |
| Klaus Veitinger | Director | Chanhassen, MN |
| Robert Jacks | Executive Officer | Portland, OR |
| Ben Auspitz | Director | Cambridge, MA |
| Karen Dawes | Director | Toronto, A6 |
| Thomas Beck | Director | Milwaukee, WI |
| Joseph Amprey | Executive Officer | Newark, NJ |
Other filings by this issuer (2)
More